September 8, 2025
Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025
August 5, 2025
Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1
July 30, 2025
Immutep Quarterly Activities Report Q4 FY25
July 29, 2025
Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer
July 28, 2025
Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025
June 23, 2025
Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases
April 23, 2025
Investor Update – April 2025
November 26, 2024
Investor Update – November 2024
February 21, 2024
Investor Update – February 2024
September 10, 2025
Wilsons – NSCLC unfazed. Bispecifics fade at WCLC. Maintain Overweight; A$1.20 PT (Analysts Dr Shane Storey and Dr Lisa Worley)
Maxim – Positive FDA Feedback in 1L H&N Cancer; Sets Stage for Potential Accelerated Path Forward – Rated Buy, US$12 PT (Analyst: Jason McCarthy, Ph.D.)
Canaccord Genuity – Turning Heads: A delineated path forward for efti in HNSCC; Maintain BUY; A$0.98 PT (Analyst: Elyse Shapiro)
Baird – FY4Q25: Ongoing Enrollment for Phase 3 1L NSCLC Study; Broad Progress; Rated OP, US$7 PT (Analyst: Colleen M. Kusy, CFA)
July 17, 2025
Wilsons – IMP761 | Can I&I success fund I-O upside? Maintain Overweight, A$1.20 TP (Analysts: Dr Shane Storey and Dr Lisa Worley)
July 11, 2025
Jefferies – Efti/Pembro Looks Good vs. Other Combos and Other Therapies in NSCLC and HNSCC; Rated BUY, PT A$2.10 (Analyst: Dr David Stanton)
Please fill out the registration form below to receive updates and announcements by e-mail.
*Required
I/We authorise you to act in accordance with my/our instructions set out above.
The privacy policy was read and accepted.
